Topics and Expertise: combination therapy

Many types of lung cancer thwart even the most targeted of therapies due to drug resistance, but a group of UCSF scientists led by Sourav Bandyopadhyay, PhD, have now shown that adding a second drug into treatment regimens can overcome this resistance in lab-grown, lung cancer cell lines.

Cancer, fundamentally, is a problem of too much growth. For decades, health care providers have tried and failed to slow tumor growth using drugs that interfere with a particular signaling pathway, called PI3K, which is known to operate in proliferating cancer cells.